{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:03:30Z","timestamp":1791583410051,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00259-024-06643-8","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T01:02:20Z","timestamp":1707872540000},"page":"1955-1964","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3792-1682","authenticated-orcid":false,"given":"Mikhail Ya.","family":"Yadgarov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9830-5686","authenticated-orcid":false,"given":"M. M.","family":"Dunaykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2410-2867","authenticated-orcid":false,"given":"G. I.","family":"Shestopalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7427-4560","authenticated-orcid":false,"given":"C.","family":"Kailash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3990-8879","authenticated-orcid":false,"given":"E. D.","family":"Kireeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4779-1896","authenticated-orcid":false,"given":"N. V.","family":"Myakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6158-2222","authenticated-orcid":false,"given":"Yu. N.","family":"Likar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"6643_CR1","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/S2352-3026(21)00349-5","volume":"9","author":"JM Kahn","year":"2022","unstructured":"Kahn JM, Pei Q, Friedman DL, et al. Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children\u2019s oncology group trials. Lancet Haematol. 2022;9:e49-57. https:\/\/doi.org\/10.1016\/S2352-3026(21)00349-5.","journal-title":"Lancet Haematol"},{"key":"6643_CR2","doi-asserted-by":"publisher","first-page":"11638","DOI":"10.18632\/oncotarget.24392","volume":"9","author":"D Perez-Callejo","year":"2018","unstructured":"Perez-Callejo D, Zurutuza L, Royuela A, et al. Long-term follow up of Hodgkin lymphoma. Oncotarget. 2018;9:11638\u201345. https:\/\/doi.org\/10.18632\/oncotarget.24392.","journal-title":"Oncotarget."},{"key":"6643_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjh.16014","volume":"187","author":"KM Kelly","year":"2019","unstructured":"Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children\u2019s Oncology Group. Br J Haematol. 2019;187:39\u201348. https:\/\/doi.org\/10.1111\/bjh.16014.","journal-title":"Br J Haematol"},{"key":"6643_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA Van Nimwegen","year":"2015","unstructured":"Van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after hodgkin lymphoma treatment 40-year disease risk. JAMA Intern Med. 2015;175:1007\u201317. https:\/\/doi.org\/10.1001\/jamainternmed.2015.1180.","journal-title":"JAMA Intern Med"},{"key":"6643_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/cncr.31807","volume":"125","author":"AS Holmqvist","year":"2019","unstructured":"Holmqvist AS, Chen Y, Berano Teh J, et al. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma\u2014Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group. Cancer. 2019;125:1373\u201383. https:\/\/doi.org\/10.1002\/cncr.31807.","journal-title":"Cancer"},{"key":"6643_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cpet.2019.03.008","volume":"14","author":"SM Bair","year":"2019","unstructured":"Bair SM, Svoboda J. Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging. PET Clin. 2019;14:353\u201368. https:\/\/doi.org\/10.1016\/j.cpet.2019.03.008.","journal-title":"PET Clin"},{"key":"6643_CR7","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1053\/j.semnuclmed.2022.10.006","volume":"53","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A, Mottaghy FM, Juweid ME. PET\/CT in Hodgkin Lymphoma: An Update. Semin Nucl Med. 2023;53:303\u201319. https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.10.006.","journal-title":"Semin Nucl Med"},{"key":"6643_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.5114\/wo.2017.68618","volume":"21","author":"E Subocz","year":"2017","unstructured":"Subocz E, Ha\u0142ka J, Dziuk M. The role of FDG-PET in Hodgkin lymphoma. Wspolczesna Onkol. 2017;21:104\u201314. https:\/\/doi.org\/10.5114\/wo.2017.68618.","journal-title":"Wspolczesna Onkol"},{"key":"6643_CR9","doi-asserted-by":"publisher","unstructured":"Kanoun S, Rossi C, Casasnovas O. [18F]FDG-PET\/CT in hodgkin lymphoma: Current usefulness and perspectives. Cancers (Basel). 2018;10. https:\/\/doi.org\/10.3390\/cancers10050145.","DOI":"10.3390\/cancers10050145"},{"key":"6643_CR10","doi-asserted-by":"publisher","unstructured":"Georgi TW, Kurch L, Hasenclever D, et al. Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial. PLoS One. 2020;15. https:\/\/doi.org\/10.1371\/journal.pone.0231027.","DOI":"10.1371\/journal.pone.0231027"},{"key":"6643_CR11","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s12149-017-1196-x","volume":"31","author":"EG Isik","year":"2017","unstructured":"Isik EG, Kuyumcu S, Kebudi R, et al. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET\/CT according to \u0394SUVmax, Deauville 5-point scale and IHP criteria. Ann Nucl Med. 2017;31:660\u20138. https:\/\/doi.org\/10.1007\/s12149-017-1196-x.","journal-title":"Ann Nucl Med"},{"key":"6643_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/ijnm.ijnm_102_22","volume":"38","author":"J John","year":"2023","unstructured":"John J, Oommen R, Hephzibah J, et al. Validation of deauville score for response evaluation in hodgkin\u2019s lymphoma. Indian J Nucl Med. 2023;38:16\u201322. https:\/\/doi.org\/10.4103\/ijnm.ijnm_102_22.","journal-title":"Indian J Nucl Med"},{"key":"6643_CR13","doi-asserted-by":"publisher","first-page":"e30580","DOI":"10.1002\/pbc.30580","volume":"70","author":"SM Castellino","year":"2023","unstructured":"Castellino SM, Giulino-Roth L, Harker-Murray P, et al. Children\u2019s Oncology Group\u2019s 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023;70:e30580. https:\/\/doi.org\/10.1002\/pbc.30580.","journal-title":"Pediatr Blood Cancer"},{"key":"6643_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40336-022-00481-0","volume":"10","author":"CCP Feres","year":"2022","unstructured":"Feres CCP, Nunes RF, Teixeira LLC, et al. Baseline total metabolic tumor volume (TMTV) application in Hodgkin lymphoma: a review article. Clin Transl Imaging. 2022;10:273\u201384. https:\/\/doi.org\/10.1007\/s40336-022-00481-0.","journal-title":"Clin Transl Imaging"},{"key":"6643_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-022-09758-z","volume":"22","author":"L van Heek","year":"2022","unstructured":"van Heek L, Stuka C, Kaul H, et al. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma \u2013 Data from the prospective, multicenter phase III HD16 trial. BMC Cancer. 2022;22:1\u20138. https:\/\/doi.org\/10.1186\/s12885-022-09758-z.","journal-title":"BMC Cancer"},{"key":"6643_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","volume":"6","author":"TJ Voorhees","year":"2022","unstructured":"Voorhees TJ, Zhao B, Oldan J, et al. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv. 2022;6:1255\u201363. https:\/\/doi.org\/10.1182\/bloodadvances.2021005385.","journal-title":"Blood Adv"},{"key":"6643_CR17","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00277-020-04039-w","volume":"99","author":"D Albano","year":"2020","unstructured":"Albano D, Mazzoletti A, Spallino M, et al. Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. Ann Hematol. 2020;99:1321\u201330. https:\/\/doi.org\/10.1007\/s00277-020-04039-w.","journal-title":"Ann Hematol"},{"key":"6643_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/jcm10194396","volume":"10","author":"I Herraez","year":"2021","unstructured":"Herraez I, Bento L, Daumal J, et al. Total lesion glycolysis improves tumor burden evaluation and risk assessment at diagnosis in hodgkin lymphoma. J Clin Med. 2021;10:10. https:\/\/doi.org\/10.3390\/jcm10194396.","journal-title":"J Clin Med"},{"key":"6643_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","volume":"131","author":"M Akhtari","year":"2018","unstructured":"Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018;131:84\u201394. https:\/\/doi.org\/10.1182\/blood-2017-04-773838.","journal-title":"Blood"},{"key":"6643_CR20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","volume":"131","author":"AS Cottereau","year":"2018","unstructured":"Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131:1456\u201363. https:\/\/doi.org\/10.1182\/blood-2017-07-795476.","journal-title":"Blood"},{"key":"6643_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4432-4","volume":"18","author":"JMM Rogasch","year":"2018","unstructured":"Rogasch JMM, Hundsdoerfer P, Hofheinz F, et al. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin\u2019s lymphoma. BMC Cancer. 2018;18:1\u20139. https:\/\/doi.org\/10.1186\/s12885-018-4432-4.","journal-title":"BMC Cancer"},{"key":"6643_CR22","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/bjh.18734","volume":"201","author":"SA Milgrom","year":"2023","unstructured":"Milgrom SA, Kim J, Pei Q, et al. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children\u2019s Oncology Group study. Br J Haematol. 2023;201:1192\u20139. https:\/\/doi.org\/10.1111\/bjh.18734.","journal-title":"Br J Haematol"},{"key":"6643_CR23","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.3390\/jcm11206223","volume":"11","author":"E Lopci","year":"2022","unstructured":"Lopci E, Elia C, Catalfamo B, et al. Prospective Evaluation of Different Methods for Volumetric Analysis on [18F]FDG PET\/CT in Pediatric Hodgkin Lymphoma. J Clin Med. 2022;11:6223. https:\/\/doi.org\/10.3390\/jcm11206223.","journal-title":"J Clin Med"},{"key":"6643_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/17474086.2023.2238125","volume":"16","author":"E Lopci","year":"2023","unstructured":"Lopci E, Mascarin M. Role of volumetric analyses on [18F]FDG PET\/CT in pediatric Hodgkin lymphoma. Expert Rev Hematol. 2023;16:629\u201331. https:\/\/doi.org\/10.1080\/17474086.2023.2238125.","journal-title":"Expert Rev Hematol"},{"key":"6643_CR25","doi-asserted-by":"publisher","unstructured":"Milgrom SA, Kim J, Chirindel A, et al. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. Pediatr Blood Cancer. 2021;68. https:\/\/doi.org\/10.1002\/pbc.29212.","DOI":"10.1002\/pbc.29212"},{"key":"6643_CR26","unstructured":"K\u00f6rholz D, Wallace WH, Landman-Parker J. European Network-Paediatric Hodgkin\u2019s Lymphoma Study Group (EuroNet-PHL). Second International Inter-Group Study for Classical Hodgkin\u2019s Lymphoma in Children and Adolescents 2016;27:1\u2013190."},{"key":"6643_CR27","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification. J Clin Oncol. 2014;32:3059\u201367. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800.","journal-title":"J Clin Oncol"},{"key":"6643_CR28","doi-asserted-by":"publisher","first-page":"145","DOI":"10.24287\/1726-1708-2022-21-1-145-154","volume":"21","author":"YN Likar","year":"2022","unstructured":"Likar YN, Yadgarov MY, Myakova NV. Predictive value of metabolic parameters of baseline 18 F-fluorodeoxyglucose positron emission tomography\/computed tomography for survival rates of children with lymphoma (a meta-analysis and literature review). Pediatr Hematol Immunopathol. 2022;21:145\u201354. https:\/\/doi.org\/10.24287\/1726-1708-2022-21-1-145-154.","journal-title":"Pediatr Hematol Immunopathol."},{"issue":"52","key":"6643_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"2018","author":"HJ Im","year":"2010","unstructured":"Im HJ, Bradshaw T, Solaiyappan M, et al. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better? Nucl Med Mol Imaging. 2010;2018(52):5\u201315. https:\/\/doi.org\/10.1007\/s13139-017-0493-6.","journal-title":"Nucl Med Mol Imaging"},{"key":"6643_CR30","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.2967\/jnumed.121.263067","volume":"63","author":"J Driessen","year":"2022","unstructured":"Driessen J, Zwezerijnen GJC, Sch\u00f6der H, et al. The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. J Nucl Med. 2022;63:1424\u201330. https:\/\/doi.org\/10.2967\/jnumed.121.263067.","journal-title":"J Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06643-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06643-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06643-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T10:04:36Z","timestamp":1717063476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06643-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6643"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06643-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a retrospective cohort study. The NMRCPHOI Independent Ethics Committee has confirmed that no ethical approval is required. All parents or persons having custody signed an informed consent for therapy, diagnostic procedures and processing of patients' personal data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}